XXII - 22nd Century Group, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
2.33
+0.01 (+0.43%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.32
Open2.31
Bid0.00 x 2900
Ask0.00 x 1000
Day's Range2.27 - 2.37
52 Week Range1.92 - 4.44
Volume1,345,820
Avg. Volume1,894,417
Market Cap289.794M
Beta2.03
PE Ratio (TTM)N/A
EPS (TTM)-0.08
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    Analysis: Positioning to Benefit within Cboe Global Markets, Sanderson Farms, National Oilwell Varco, Brighthouse Financial, VeriSign, and 22nd Century Group — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Aug. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cboe ...

  • Associated Press12 days ago

    22nd Century: 2Q Earnings Snapshot

    On a per-share basis, the Williamsville, New York-based company said it had a loss of 5 cents. The plant biotechnology company posted revenue of $6.9 million in the period. In the final minutes of trading ...

  • Business Wire12 days ago

    22nd Century Files 2018 Second Quarter Report

    Company significantly increases spending and strategic initiatives in support of MRTP application and FDA’s ANPRM for reduced nicotine cigarettes. 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine tobacco, and hemp/cannabis research, announced today the Company’s second quarter 2018 financial results. 22nd Century will provide a business update for investors on a conference call to be held Wednesday, August 8, 2018, at 4:00 PM (Eastern Time).

  • Who Are The Top Investors In 22nd Century Group Inc (NYSEMKT:XXII)?
    Simply Wall St.12 days ago

    Who Are The Top Investors In 22nd Century Group Inc (NYSEMKT:XXII)?

    In this analysis, my focus will be on developing a perspective on 22nd Century Group Inc’s (NYSEMKT:XXII) latest ownership structure, a less discussed, but important factor. The impact of aRead More...

  • Business Wire19 days ago

    Washington Examiner Publishes Public Policy Article by 22nd Century’s James Vail and Juan Sanchez Tamburrino, Ph.D.

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that The Washington Examiner published an op-ed article by James Vail, Director of Communications, and Juan Sanchez Tamburrino, Ph.D. Vice President of Research and Development, at 22nd Century. The article calls for the U.S. Congress, tobacco control advocates, and the American people “to ensure that the FDA’s nicotine reduction plan quickly becomes reality.” Dr. Scott Gottlieb, Commissioner of the U.S. Food and Drug Association (FDA), has stated that the FDA’s efforts to lower nicotine in cigarettes will be based on science.

  • Business Wire26 days ago

    Nondaily Smokers Who Switch to 22nd Century’s Very Low Nicotine Content Cigarettes Reduce their Consumption by a Staggering 51%

    In conducting this important clinical trial, study authors Saul Shiffman, Ph.D., Brenda Kurland, Ph.D., Sarah Scholl, MPH, and Jason Mao, B.S. used 22nd Century’s proprietary SPECTRUM® VLNC cigarettes and standard nicotine content cigarettes.

  • Business Wirelast month

    22nd Century Announces the Immediate Feasibility of the FDA’s Nicotine Reduction Plan

    22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, yesterday responded to the Advance Notice of Proposed Rulemaking (ANPRM) by the U.S. Food and Drug Administration (FDA) to develop a rule that will require all cigarettes sold in the United States to contain only minimally or non-addictive levels of nicotine. When the Company’s response is posted online by the FDA at www.regulations.gov, the corresponding tracking number will be: 1k2-94b8-wdcp. 22nd Century’s complete response to the FDA’s ANPRM is currently available at: www.xxiicentury.com/ANPRM.

  • Is This Former Top-Performing Marijuana Stock Now a Bargain?
    Motley Foollast month

    Is This Former Top-Performing Marijuana Stock Now a Bargain?

    22nd Century Group was a top-performing marijuana stock last year, but things have drastically changed for the company halfway into 2018.

  • Here's Why Marijuana and Tobacco Stock 22nd Century Group Rose 16% in June
    Motley Foollast month

    Here's Why Marijuana and Tobacco Stock 22nd Century Group Rose 16% in June

    ETFs and mutual funds are adding the company. Should you?

  • Business Wirelast month

    22nd Century Reports on New Responses to the FDA’s Nicotine Reduction Plan

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, today highlights two important submissions to the U.S. Food and Drug Administration (FDA). Altogether, nine separate researchers authored these particular submissions in response to the FDA’s Advance Notice of Proposed Rulemaking (ANPRM) to require that nicotine levels in combustible cigarettes be lowered to minimally or non-addictive levels. 22nd Century’s proprietary VLN™ tobacco cigarettes were used by the FDA in formulating the Agency’s plan to dramatically reduce the nicotine content of cigarettes.

  • ACCESSWIRElast month

    Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities

    Stock Research Monitor: RGNX, RGLS, and ABEO LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on XXII sign up now at www.wallstequities.com/registration . For today, WallStEquities.com ...

  • Business Wire2 months ago

    22nd Century Highlights Public Comments to the FDA’s Nicotine Reduction Plan

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, today called attention to comments submitted to the U.S. Food and Drug Administration (FDA) in response to the FDA’s Advance Notice of Proposed Rulemaking (ANPRM) to develop a nicotine product standard in cigarettes that will lower nicotine to minimally or non-addictive levels.

  • Business Wire2 months ago

    22nd Century Announces New Non-GMO, Very Low Nicotine Flue-Cured and Burley Tobacco Varieties

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, announced today that the Company has exclusively licensed from North Carolina State University (NCSU) several flue-cured and burley tobacco plant lines that grow with Very Low Nicotine levels. The new, non-GMO, Very Low Nicotine tobacco plant lines are immediately commercially viable as they are the result of multiple generations of plantings that have yielded stable, true-breeding crop lines of Very Low Nicotine flue-cured and burley tobacco plants.

  • Business Wire2 months ago

    22nd Century Group Added to Russell 2000, Russell 3000 and Russell Global Indexes

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine tobacco, and hemp/cannabis research, announced today that the Company was added to the Russell 2000, Russell 3000, and Russell Global indexes on June 22, 2018 when Russell FTSE (Russell) reconstituted its U.S. and global equity indexes. Russell added 22nd Century to the Russell Microcap index in 2017.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Stocks to Watch: 22nd Century Group and Palatin Technologies

    NEW YORK, NY / ACCESSWIRE / June 25, 2018 / Both 22 nd Century Group and Palatin Technologies saw their shares jump on Friday despite either company announcing any significant news. RDI Initiates Coverage ...

  • Business Wire2 months ago

    22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine Content tobacco, announced that the Company has initiated three short-term studies investigating the behavioral and biochemical responses to the Company’s proprietary Very Low Nicotine Content tobacco. 22nd Century scientists will submit to the FDA the data collected from these studies as part of the Company’s revised and enhanced Modified Risk Tobacco Product (MRTP) application for “BRAND A” Very Low Nicotine Content cigarettes.

  • Business Wire2 months ago

    22nd Century Group to be Added to Russell 2000, Russell 3000, and Russell Global Indexes

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine tobacco, and hemp/cannabis research, announced today that the Company will be added to the Russell 2000, Russell 3000, and Russell Global Indexes when FTSE Russell (Russell) reconstitutes its U.S. and global equity indexes on June 22, 2018. Russell’s preliminary announcement of its annual reconstitution of these Indexes, which includes 22nd Century Group, was posted on the Russell website on Friday, June 8, 2018, after the U.S. stock market closed.

  • ACCESSWIRE2 months ago

    Free Technical Research on Versartis and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).

  • Business Wire2 months ago

    22nd Century to Present to Institutional Investors at the Citi 2018 Small & Mid Cap Conference

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine tobacco, and hemp/cannabis research, today announced that the Company will present at the Citi 2018 Small & Mid Cap Conference at the Lotte New York Palace Hotel, New York, NY on Wednesday, June 6, 2018 at 8:00AM Eastern Time. Henry Sicignano III, President and Chief Executive Officer of 22nd Century Group, will deliver a formal presentation to institutional investors and will discuss the Company’s recent business highlights and updates. Mr. Sicignano will also be available for one-on-one meetings with investors at the conference.

  • Business Wire3 months ago

    Altria, Reynolds, Lorillard, and Philip Morris Ordered to Issue Corrective Statements on Nicotine Addiction; 22nd Century’s Proprietary VLN (TM) Tobacco Called “Minimally or Non-Addictive”

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, announced that on May 1, 2018, a federal court ordered Altria, R.J. Reynolds Tobacco, Lorillard, and Philip Morris USA to issue statements to correct marketing that deliberately deceived the public about the addictiveness and health risks of smoking.

  • Benzinga3 months ago

    Cannabis Hedge Fund Managers On The Two Biggest Problems Marijuana Businesses Face

    A few weeks ago, Benzinga had the chance to visit the offices of Poseidon Asset Management, a San Francisco-based cannabis-focused long/short hedge fund with more than $40 million in assets under management. Co-founder and managing partner Emily Paxhia mentioned and her brother and partner Morgan Paxhia have helped turn around multiple companies.

  • Business Wire3 months ago

    Public Health Leaders Urge FDA to Issue Final Rule for Reducing Nicotine in Cigarettes by March 2019

    22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, announced today that 41 public health and medical organizations wrote an open letter to Dr. Scott Gottlieb, Commissioner of the U.S. Food and Drug Administration (FDA), urging the FDA to quickly implement its plan to reduce nicotine in cigarettes to minimally or non-addictive levels. 22nd Century is the only company in the world that has grown commercial crops of proprietary tobacco with nicotine levels of just 0.4mg per gram of tobacco – a 95% reduction in nicotine as compared to tobacco used in conventional cigarettes.

  • Benzinga3 months ago

    Marijuana In College: Why Universities Are Offering Cannabis-Focused Classes (And Where You Can Find Them)

    The legal cannabis industry is growing at an unprecedented pace. This figure is expected to surge to roughly $35 billion by 2022, GreenWave Advisors managing partner Matt Karnes told Benzinga in a recent conversation. “We expect that by 2022, all states will have implemented either a medical only or fully legal marijuana market,” he said.

  • Push to add women to WNY boards gains momentum
    American City Business Journals3 months ago

    Push to add women to WNY boards gains momentum

    A review of annual proxy statements filed in 2007 shows that women held 5 percent of board seats at the region’s publicly traded companies that year. By 2017 that figure had crept up to about 10.5 percent.

  • Why 22nd Century Group Inc (NYSEMKT:XXII) Could Be A Buy
    Simply Wall St.3 months ago

    Why 22nd Century Group Inc (NYSEMKT:XXII) Could Be A Buy

    22nd Century Group Inc (AMEX:XXII), a tobacco company based in United States, saw a decent share price growth in the teens level on the AMEX over the last few months.Read More...